Biodesix presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules.
Biodesix, Inc. is proud to announce that its CFO, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors.
Biodesix announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.
Biodesix announces its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.
Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person investor meetings at Cowen’s 43rd Annual Healthcare Conference.
Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update.
announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York
Biodesix announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors effective January 3, 2023.
Biodesix named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine issue, Top 10 Proteomics Solutions Companies of 2022.
Biodesix announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.